A growing number of women are opting to go in for surgery to treat endometrial cancer.
But a study published this week suggests it might not be a cure-all for the disease.
The results of the new study suggest that the number of patients seeking treatment for endometrium may not be the best predictor of whether a patient will respond well to surgery, as many women may have a genetic predisposition.
“The data suggests that there may be some patients with an underlying genetic predispose that predisposes them to surgery that they will not respond to,” said Dr. Laura E. Johnson, an endometrist at the University of Utah Medical Center.
But the study’s results are far from conclusive.
In fact, some of the women in the study were not eligible for the procedure, as they had an underlying disease, and they may not have had an appropriate history of endometria.
“What I find interesting about this study is that in all the patients who were eligible for surgery, they were treated with a single agent, so this may be a marker that it is a treatment that works,” said Johnson.
But Johnson also emphasized that it’s too soon to know whether endometrin surgery will lead to a cure for endovascular disease.
“There is some evidence that there is some benefit with a combination of these two agents that are combined,” she said.
“I don’t think we should conclude that the endovidion has all the answers.”
For those women who do need surgery, the surgery will usually take about three months to complete.
“I think that the overall message is that you can’t just go to surgery and say, ‘Oh, well, I have endometric cancer, I need to get surgery,'” said Johnson, who is also a professor at the U.S. University of California, San Francisco.
The study was published in the journal Archives of Internal Medicine.